Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoblituzumab + Pembrolizumab/Retifanlimab in Advanced Cancers
NCT02475213Phase 1Completed
- Sponsor
- MacroGenics
- Start
- Jul 2015
- Primary completion
- Aug 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of enoblituzumab in melanoma, head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC) and 1 more (8 cohorts), sponsored by MacroGenics. Primary endpoint: Number of Participants With Dose-limiting Toxicities. Started Jul 2015; status: completed.
02
Drugs
enoblituzumab
03
Conditions
melanomahead and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02475213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02475213.